Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Inc.

www.apotex.com

Latest From Apotex Inc.

Australian Court Restrains Apotex Challenge To Cipla-Meda’s Dymista

Apotex’s plans to launch a nasal spray formulation that competes with Cipla-Meda’s Dymista has been blocked by the Federal Court of Australia, at least for now. Apotex has challenged the validity of certain claims of the patent pertaining to Dymista.

Commercial Companies

Australian Court Restrains Apotex Challenge To Cipla-Meda’s Dymista

Apotex’s plans to launch a nasal spray formulation that competes with Cipla-Meda’s Dymista has been blocked by the Federal Court of Australia, at least for now. Apotex has challenged the validity of certain claims of the patent pertaining to Dymista.

Commercial Companies

Namenda XR Generics Coming Soon? US Court Rulings Clear Path For Multiple Launches

Seven companies hold final ANDA approval for Alzheimer's drug, but Allergan still has chance to block them as it seeks rehearing of appeals court's patent decision. Meanwhile, Amneal might block other generics if it can get an appeals court to grant it the 180-day marketing exclusivity for memantine extended-release it says that FDA unfairly denied it.

Generic Drugs Legal Issues

Panacea-Serum Team Up To Take Six-In-One Vaccine Global

Panacea Biotec has allied with the world’s largest-vaccine maker, the Serum Institute of India, to ramp up production of a six-in-one jab aimed at preventing killer diseases like polio and diphtheria and target a global market estimated to be worth over $1.25bn annually.

Commercial Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register